Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

500.00 +3.51 (+0.71%)
Streaming Delayed Price Updated: 10:10 AM EDT, Apr 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
Via The Motley Fool
Topics Artificial Intelligence Energy
Exposures Artificial Intelligence Fossil Fuels
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Via The Motley Fool
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Via The Motley Fool
Topics Government
Exposures Political
Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts
Via Benzinga
Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right
Via The Motley Fool
Topics Economy Government World Trade
Exposures Economy Interest Rates Political
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely
Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and potential upside surprises. 
Via Benzinga
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
As The Nasdaq 100 Index Crashes, Is It Safe To Buy The Dip?
The Nasdaq 100 Index remains under pressure after forming a death cross pattern a few weeks ago. It has retreated to $18,257, down by over 17.8% from its highest point this year. 
Via Talk Markets
Topics Stocks / Equities
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Exposures Political
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Economy Political
Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
Exposures Artificial Intelligence Political Tariff
CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades'
CrowdStrike has expanded its partnership with Google Cloud to enable end-to-end security for AI innovation. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.
Via The Motley Fool
Topics Economy Government World Trade
Exposures Interest Rates Political Tariff
5 Top Growth Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Government
Exposures Political
Is Vertex Pharmaceuticals Stock a Buy?
Via The Motley Fool
Exposures Product Safety
These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue?
A group of S&P 500 stocks have remained resilient as tariffs and earnings concerns cause the market to drop. Future gains may be limited. 
Via Benzinga
Topics Stocks World Trade
Exposures Tariff US Equities
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy. 
Via Benzinga
2 Stocks to Buy if You're Worried About a Recession
Via The Motley Fool
Topics Economy Government
Exposures Economy Political
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the Storm
Via The Motley Fool
Topics Earnings Economy Government
Exposures Economy Financial Political
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.
Via The Motley Fool
Topics Economy Energy Government
Exposures Economy Fossil Fuels Interest Rates
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy. 
Via Stocktwits
Topics ETFs Government
Exposures COVID-19 Political Product Safety
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
Via Benzinga
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.